1. Clinical & Scientific Overview
Pantoprazole Sodium Sesquihydrate (TIP-MED-000069, Reference Code [5.1]) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Proton Pump Inhibitor (PPI); Irreversible Gastric Parietal Cell H+/K+-ATPase Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Essential Medicine.
Thyronorm (Abbott), Eltroxin (GSK), Thyrox (Macleods)
Enteric-Coated (Gastro-Resistant) Tablets: 20 mg, 40 mg; Lyophilised Powder for IV Injection: 40 mg/vial
3. Mechanism of Action & Pharmacodynamics
Weakly basic prodrug (pKa ~4) absorbed intact from the duodenum via an enteric-coated formulation. Accumulates selectively in the highly acidic secretory canaliculi of stimulated gastric parietal cells (pH ~1.0), where it undergoes acid-catalysed rearrangement into an active tetracyclic sulfenamide that forms irreversible covalent disulfide bonds with Cysteine-813 and Cysteine-822 on the luminal H+/K+-ATPase proton pump, suppressing basal and stimulated acid secretion for 24+ hours.
4. Therapeutic Indications & Evidence-Supported Uses
- Gastro-oesophageal reflux disease (GORD) and erosive oesophagitis
- Peptic ulcer disease (gastric & duodenal ulcers) and H. pylori eradication regimens
- NSAID/antiplatelet-induced ulcer prophylaxis and Zollinger-Ellison syndrome
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults (GORD / Peptic Ulcer): 40 mg orally once daily 30–60 minutes before breakfast for 4–8 weeks. IV (Acute Upper GI Bleed): 80 mg IV bolus followed by 8 mg/hr infusion or 40 mg IV q12h.
Administration & Meal Timing: Oral (swallow enteric-coated tablet whole 30–60 minutes before morning meal) or Intravenous.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
In severe hepatic cirrhosis (Child-Pugh C), t1/2 increases to 7–9 hours; limit maximum dose to 20–40 mg/day or alternate-day dosing.
No dose adjustment required in renal impairment.
In severe hepatic cirrhosis (Child-Pugh C), t1/2 increases to 7–9 hours; limit maximum dose to 20–40 mg/day or alternate-day dosing.
7. Contraindications, Precautions & High-Risk Warnings
- Hypersensitivity to substituted benzimidazoles
- Concomitant Rilpivirine or Atazanavir (profound reduction in antiretroviral absorption due to elevated gastric pH)
Key Clinical Precautions: In severe hepatic cirrhosis (Child-Pugh C), t1/2 increases to 7–9 hours; limit maximum dose to 20–40 mg/day or alternate-day dosing.
8. Adverse Effects Profile
- Short-term: headache, mild diarrhoea, nausea, abdominal flatulence
- Long-term (>1 year): hypomagnesaemia, Vitamin B12 and iron malabsorption, osteoporotic hip/wrist/spine fractures, C. difficile colitis, and acute interstitial nephritis (AIN)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- pH-dependent oral drugs (Ketoconazole, Itraconazole, Iron salts, Cefpodoxime, Erlotinib, Atazanavir): elevated gastric pH reduces dissolution and bioavailability
- Clopidogrel: Pantoprazole causes significantly less CYP2C19 inhibition than Omeprazole/Esomeprazole and is the preferred PPI in dual antiplatelet therapy (DAPT)
- Methotrexate (high-dose): PPIs inhibit renal H+/K+ and OAT3 elimination of Methotrexate, delaying clearance
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Swallow the gastro-resistant tablet WHOLE 30–60 minutes before breakfast (when parietal proton pumps are maximally activated by the meal).
- Never crush, split, or chew the tablet, as stomach acid will destroy the medicine before it is absorbed.
- Reassess the need for chronic daily PPI therapy after 4–8 weeks to avoid long-term nutrient deficiency.
Storage, Stability & Dispensing Safeguards: Store below 25–30°C protected from moisture.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.